



- (51) International Patent Classification:
G01N 33/50 (2006.01)
- (21) International Application Number:
PCT/SG2021/050767
- (22) International Filing Date:
07 December 2021 (07.12.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10202012586X 15 December 2020 (15.12.2020) SG
- (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).
- (72) Inventors: NG, Lai Guan; c/o Singapore Immunology Network, 8a Biomedical Grove, Level 3 Immunos Building,

Singapore 138648 (SG). NG, Shu Feng, Melissa; c/o Singapore Immunology Network, 8a Biomedical Grove, Level 3 Immunos Building, Singapore 138648 (SG). TAN, De Li, Leonard; c/o Singapore Immunology Network, 8a Biomedical Grove, Level 3 Immunos Building, Singapore 138648 (SG). GINHOUX, Florent, Benoit, Claude; c/o Singapore Immunology Network, 8a Biomedical Grove, Level 3 Immunos Building, Singapore 138648 (SG).

(74) Agent: DONALDSON & BURKINSHAW LLP; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: A METHOD OF CHARACTERISING AN IMMUNOSUPPRESSIVE NEUTROPHIL




Fig. 2 (Continued)

(57) Abstract: The invention relates to a method of detecting and/or characterising an immunosuppressive neutrophil comprising determining and/or measuring the expression of one or more anti-apoptotic markers in a neutrophil population. In an embodiment, the immunosuppressive neutrophil is a polymorphonuclear myeloid-derived suppressor cell (PMNMDSC) and the anti-apoptotic marker is TNF-related apoptosis-inducing ligand (TRAIL)-receptor 3 (TRAILR3/TNFRSF10C) and/or decoy TNF-related apoptosis-inducing ligand (TRAIL)-receptor (dcTRAILR1). Also disclosed are methods of evaluating the progression of a proliferative disease in a subject, methods of evaluating the efficacy of a treatment regimen for a proliferative disease in a subject, methods of treating a proliferative disease in a subject, and kits thereof.

[Continued on next page]

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*